Corline Biomedical AB (STO:CLBIO)
16.00
-0.15 (-0.93%)
Sep 2, 2026, 4:54 PM CET
Corline Biomedical AB Revenue
Corline Biomedical AB had revenue of 4.75M SEK in the quarter ending June 30, 2026, with 80.85% growth. This brings the company's revenue in the last twelve months to 12.82M, down -56.27% year-over-year. In the year 2025, Corline Biomedical AB had annual revenue of 8.62M, down -51.27%.
Revenue (ttm)
12.82M
Revenue Growth
-56.27%
P/S Ratio
35.61
Revenue / Employee
911.69K
Employees
13
Market Cap
422.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.62M | -9.07M | -51.27% |
| Dec 31, 2024 | 17.69M | -18.25M | -50.78% |
| Dec 31, 2023 | 35.93M | 2.60M | 7.80% |
| Dec 31, 2022 | 33.33M | 16.07M | 93.09% |
| Dec 31, 2021 | 17.26M | 2.16M | 14.29% |
| Dec 31, 2020 | 15.10M | 3.15M | 26.36% |
| Dec 31, 2019 | 11.95M | 2.42M | 25.35% |
| Dec 31, 2018 | 9.54M | -6.62M | -40.98% |
| Dec 31, 2017 | 16.16M | 5.79M | 55.87% |
| Dec 31, 2016 | 10.37M | 6.86M | 195.50% |
| Dec 31, 2015 | 3.51M | -140.83K | -3.86% |
| Dec 31, 2014 | 3.65M | -614.17K | -14.41% |
| Dec 31, 2013 | 4.26M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.31M |
| Sprint Bioscience AB | 138.95M |
| Oncopeptides AB | 95.15M |
| Xbrane Biopharma AB | 83.30M |
| IRLAB Therapeutics AB | 79.33M |
| Intervacc AB | 18.11M |
| Xspray Pharma AB | 2.47M |
| FluoGuide | 404.33K |
Corline Biomedical AB News
- 7 days ago - Corline Biomedical AB Quarterly report: Q2 2026 - Filings
- 3 months ago - Corline Biomedical AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Corline Biomedical AB Quarterly report: Q4 2025 - Filings
- 6 months ago - Corline Biomedical AB Annual report: Q4 2025 - Filings
- 9 months ago - Corline Biomedical AB Quarterly report: Q3 2025 - Filings